COVID-19 pandemic accelerating global health crisis caused by antibiotic overuse and misuse
bioMérieux Inc., has partnered with SAS to help combat antimicrobial resistance. As professionals from around the world gather to discuss health analytics and technology at the HIMSS annual conference this week, the companies announced the development of a pioneering analytics solution to arm frontline clinicians with real-time health data for better, faster infection treatment.
The new software-as-a-service offering, BIOMÉRIEUX CLARION, connects the myriad of healthcare data inside US hospitals and reference laboratories to provide critical insights to battle public health threats. The solution tracks antimicrobial-resistant (AMR) bacteria and quickly produces data dashboards on SAS Viya to empower more informed clinical decision making.
The partnership is rooted in the medical community’s ongoing fight against antimicrobial resistance and the goal to activate and support continuous improvement within antimicrobial stewardship programs.
The Centers for Disease Control and Prevention (CDC) recommends all U.S. hospitals develop an antimicrobial stewardship program to help eliminate drug-resistant superbugs and improve patient health outcomes. The CLARION advanced analytics software provides critical lab and clinical data across departments, processes and vendors, including regional surveillance of multidrug-resistant organisms, customizable alerts for antibiotic utilization and proof points for federally mandated antimicrobial stewardship program performance elements.